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Abstract
Kojonazarov, Baktybek, Jainagul Isakova, Baktybek Imanov, Nurmira Sovkhozova, Talantbek Sooronbaev,
Takeshi Ishizaki, and Almaz A. Aldashev. Bosentan reduces pulmonary artery pressure in high altitude resi-
dents. High Alt Med Biol. 13:217–223, 2012.—Endothelin-1 (ET-1) plays a critical role in the regulation of pul-
monary vascular tone. The aim of this study was to investigate the role of ET-1 in the pathogenesis of high
altitude pulmonary arterial hypertension (HAPH). Methods: Pulmonary artery pressure (PAP) was measured by
echocardiography in permanent residents of the Kyrgyz Republic (3200–4000 m above sea level) both before and
3 h after a single oral dose of ET receptor antagonist, bosentan (125 mg). Plasma ET-1 levels were measured by
ELISA assay. Genomic DNA was extracted from peripheral blood samples and the frequency of -3a and -4a
alleles of the ET-1 gene determined by PCR. Results: Plasma ET-1 in HAPH highlanders was significantly higher
than in healthy subjects (7.05 – 2.35 vs. 4.65 – 1.65 pg/ml, p < 0.002). After the treatment with 125 mg bosentan,
systolic PAP decreased from 46 – 1.9 to 37 – 2.2 mm Hg ( p < 0.01), and pulmonary artery acceleration time
(PAAT) increased from 0.086 – 0.001 to 0.098 – 0.001 sec ( p < 0.001). The frequency of the -4a allele was signifi-
cantly higher in HAPH patients compared to healthy highlanders (0.43 vs. 0.3, v2 = 4.3, p = 0.03). Conclusion:
Increased ET-1 levels play an important role in development of HAPH.
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Introduction
An estimated 4%–6% of Kyrgyz residents of the Tien-Shan and Pamir Mountains (3000–3500 m above sea
level) in the Kyrgyz Republic develop high-altitude pulmo-
nary hypertension (HAPH) with right ventricular failure
(Mirrakhimov and Winslow, 1996). HAPH is characterized by
increased pulmonary artery pressure (PAP) and pulmonary
vascular remodeling involving all elements of the vessel
wall, including endothelial and smooth muscle cells and
fibroblasts (Arias-Stella and Saldana, 1963; Aldashev, 2000;
Leon-Velarde et al., 2005).
A number of factors are known to influence the develop-
ment of HAPH and the large interindividual variability in the
magnitude of PAP response to hypoxia has been demon-
strated by several studies (Westcott et al., 1955; Groves et al.,
1993; Aldashev et al., 2002). Moreover, the genetic suscepti-
bility to high altitude-related illness is suggested (Weir et al.,
1974; Morrell et al., 1999; Aldashev et al., 2002; Droma et al.,
2002; Droma et al., 2006).
The prevailing view is that imbalances of endogenous
vasodilator and vasoconstrictor factors contribute to pul-
monary vascular vasoconstriction and structural remodeling
(Humbert et al., 2004). Endothelin-1 (ET-1) is a one of the
most potent vasoconstrictors produced by vascular tissue
(Yanagisawa and Masaki, 1989). Several studies have dem-
onstrated elevated ET-1 levels in experimental hypoxic pul-
monary hypertension (PH) (Shirakami et al., 1991; Li et al.,
1994; Yang et al., 1997) and in patients with idiopathic pul-
monary arterial hypertension (PAH) and PH associated with
other diseases (Stewart et al., 1991; Giaid et al., 1993; Mac-
Lean, 1998). Moreover, the plasma level of ET-1 correlates
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with right atrial pressure, pulmonary vascular resistance,
and survival of patients with PAH (Nootens et al., 1995;
Cacoub et al., 1997).
The acute increase in PAP seen in mountaineers on ex-
posure to hypoxia has been reported to be closely related to
elevated plasma ET-1 levels (Goerre et al., 1995). Further-
more, it has been demonstrated subjects prone to high al-
titude pulmonary edema (HAPE) had higher ET-1 plasma
levels than the subjects resistance to this condition, and
ET-1 levels closely related to PAP measured at high altitude
(Sartori et al., 1999). Also, Droma and co-authors published
a case study in which elevated plasma ET-1 in patient with
acute HAPE occurred at 3180 m altitude returned to normal
levels after oxygen inhalation at 660 m altitude (Droma
et al., 1996).
The ET-1 gene located on chromosome 6p24–23, consists
of 5 exons and encodes pre-pro-ET, which is cleaved into
ET-1 (Yanagisawa 1989; Xu et al., 1994). Numerous studies
suggested that single nucleotide polymorphisms in the ET-1
gene contribute to development of cardiovascular disorders
and are associated with high level of plasma ET-1 (Asai
et al., 2001; Tanaka et al., 2004; Dong et al., 2004). Also
Rajput and co-authors investigated four ET-1 variants in
Himalayan natives and found that in subjects with mutant
heterozygous genotype 3a/4a, ET-1 plasma level was sig-
nificantly higher than in highlanders with homozygous
3/3a genotype. However, the association between ET-1
gene polymorphism and development of HAPH is still to be
elucidated.
Additionally, dual ET receptor antagonist, bosentan effec-
tively attenuates hypoxic pulmonary vasoconstriction in
healthy subjects (Modesti et al., 2006; Pham et al., 2010).
However, it has been reported that bosentan improves aerobic
exercise capacity in a hypoxic environment (Faoro et al., 2009),
while another report demonstrated that bosentan does not
reduce resting or exercise systolic PAP or improve exercise
capacity (Seheult et al., 2009). The efficacy of ET-1 inhibition in
patients with HAPH remains to be demonstrated.
The main aim of this study was to investigate the acute
effect of 125 mg of bosentan on PAP and the potential role of
endothelin-1 gene polymorphism in patients with HAPH.
Methods
The ethics committee of the Institute of Molecular Biology
and Medicine and National Center of Cardiology and Internal
Medicine (Bishkek, Kyrgyzstan) approved the study and
followed international guidelines for medical research on
human subjects. All subjects included in this study gave in-
formed consent in a written form.
Patients
138 residents of villages 2500–3800 m above sea level in
the Tien-Shan Mountains of the Kyrgyz Republic with
symptoms of dyspnea or exercise limitation as recorded at
the local high altitude clinics were admitted to the National
Center of Cardiology and Internal Medicine (Bishkek, 760 m
above sea level) in a period from 2006 to 2008. All subjects
underwent health screening by history, physical examina-
tion, ECG, echocardiography, spirometry, blood pressure
measurement, and biochemical analysis for liver and kid-
ney function for excluding coexisting diseases that might
influence PAP.
Right heart catheterization
Right heart catheterization was performed within 1 week of
descent to Bishkek, as described previously (Aldashev et al.,
2005; Kojonazarov et al., 2007). Briefly, a Swan-Ganz catheter
(Baxter Healthcare, Compton, UK) introduced via an internal
jugular vein, and after 30 min of rest, the mean PAP and
pulmonary artery wedge pressure were measured during
end-expiration. Arterial oxygen saturation, ECG, and blood
pressure were monitored throughout the experiment. During
the catheterization study, blood samples for DNA analysis
were taken. HAPH was defined according to the consensus
recommendation (Leon-Velarde et al., 2005). Eighty-eight
subjects were found to have HAPH and 50 had normal
pressures.
Acute bosentan study protocol
An acute bosentan study was performed during expedition
to high altitude. Fifteen nonsmoker patients with HAPH,
underwent echocardiography examinations on 2 occasions,
1 day apart, at a clinic in their home village (3200–3800 m). On
the first day, Doppler-echocardiography were performed
before and 30 min after 100% oxygen. On the second day,
echocardiographic measurements were performed before
and 3 hours after a single oral dose of bosentan (125 mg).
All subjects then breathed 100% oxygen for 30 min, and
echocardiography was repeated. SaO2, HR, and systemic
blood pressure (BP) were monitored continuously during
echocardiography.
Echocardiography
Doppler-echocardiography was performed using a por-
table ultrasound system equipped by a 2.5 MHz probe
(SpectraMax, SonoSite, USA). Pulmonary artery systolic
pressure (PAPs) and pulmonary artery acceleration time
(PAAT) were estimated as previously described (Kitabatake
et al., 1983; Yock and Popp, 1984). Briefly, images were ob-
tained from standard parasternal views (long axis and short
axis) and an apical four-chamber view. The PAPs was cal-
culated using the modified Bernoulli equation (PASP = 4
VTR2 + right atrial pressure), where VTR is the tricuspid
regurgitation peak velocity recorded from multiple jet
windows with continuous-wave Doppler, and right atrial
pressure is estimated from the vena cava diameter variations
(Yock and Popp, 1984). A pulsed Doppler pulmonary blood
flow velocity signal was sampled in the right ventricular
outflow tract for the estimation of PAAT, which was defined
as the time interval from the onset of forward flow in
the pulmonary artery to the peak velocity of this flow as
described (Kitabatake et al., 1983). Cardiac output was esti-
mated from left ventricular outflow tract cross-sectional area
and pulsed Doppler velocity-time integral measurements.
All measurements were performed by an experienced
echocardiographer and validated by another independent
observer.
Measurements of plasma ET-1 level
Blood samples were taken from 37 highlanders (17 with
HAPH and 20 healthy) at high altitude. The samples were
immediately put on ice and then centrifuged at 3000 rpm for
10 min. Plasma samples were then snap-frozen in liquid ni-
trogen until their return to the laboratory, where ET-1 con-
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centrations were measured by ELISA assay (R&D, Germany)
according to the supplied protocol.
ET-1 gene polymorphism
The -3a/-4a polymorphism of ET-1 gene was determined in
138 highlanders by polymerase chain reaction (PCR); the
following primers were used 5¢-TTGTCTGGGGCTGGAA-
TAAAGTGG-3¢ and 5¢-CGAGCGTGCCTACCTGTTTCTG-3¢.
The products of PCR were digested by Bse II enzyme and
separated by 2% agarose DNA electrophoresis as described
(Rajput et al., 2006).
Statistical analysis
All data are given as means – SD. Differences between
groups were assessed by unpaired two-sample Student t test
and analysis of variance, and Student-Newman-Keuls post-
hoc test for multiple comparisons with a p value £ 0.05 re-
garded as significant. Frequency of genotype or allele of ET-1
was compared by use of the contingency table, and signifi-
cance of difference was examined by v2 analysis.
Results
Subjects
138 residents of villages 2500–3800 m above sea level un-
derwent right heart catheterization and health screening at
Bishkek (760 m above sea level). After right heart catheteri-
zation, 88 were defined as HAPH patients and 50 as healthy
with normal PAP. The baseline characteristics of the HAPH
and control groups are shown in Table 1. There were no
differences in HAPH and control groups in terms of age,
male/female ratio, and spirometrical data except PAP. There
were no coexisting diseases other than HAPH in patients
group.
-3a/-4a polymorphism of ET-1 gene and HAPH
The -3a/-4a polymorphism of ET-1 gene polymorphism was
investigated in 138 subjects who underwent right heart cathe-
terization. The frequency of homozygous -3a/-3a genotype
was higher in healthy highlanders compared to HAPH sub-
jects, and the frequency of heterozygous -3a/-4a was higher in
highlanders with HAPH (v2= 11.15; p< 0.001). Accordingly the
frequency of the mutant -4a allele was significantly higher in
highlanders with HAPH compared with healthy controls
(v2= 4.3; p< 0.03, Table 2). The mutant homozygous -4a/-4a
genotype was not detected in highlanders
Plasma ET-1 level
Blood samples were taken from 37 highlanders (17 with
HAPH and 20 healthy) at high altitude, and ET-1 levels were
measured by ELISA in Bishkek (760 m). Plasma ET-1 levels in
highlanders with HAPH were significantly higher than
those seen in healthy control subjects (7.07 – 2.26 and 4.56 –
1.66 pg/ml, respectively, p < 0.001, Fig. 1A). Subjects expres-
sing the heterozygous - 3a/-4a genotype had higher ET-1
concentrations (6.16 – 0.48 pg/ml) than subjects with homo-
zygous 3a/3a genotype (4.81 – 0.57 pg/ml, p< 0.07, Fig. 1B).
Effects of oxygen breathing on pulmonary
arterial pressure
On the first day, Doppler-echocardiography was per-
formed before and 30 minutes after 100% oxygen in 15 non-
smoker patients with HAPH, at a clinic in their home village
(3200–3800 m). Oxygen significantly increased PAAT by
0.014– 0.002 sec (95% CI 0.01 to 0.02, p< 0.001) and decreased
PAPs by - 8.5 – 3.19 (95% CI - 1.7 to - 15.2, p < 0.01). Whereas
CO, systemic BP, and HR did not change significantly during
oxygen breathing, SaO2 markedly increased during oxygen
breathing ( p< 0.001).
Effects of bosentan on PAP
On the second day, echocardiographic measurements were
performed before and 3 hours after a single oral dose of bo-
sentan (125 mg). All 15 subjects then breathed 100% oxygen
for 30 min, and echocardiography was repeated. Systolic
PAP was significantly reduced by - 10.6 – 4.9 mm Hg (95%
CI - 6.5 to - 14.7 mmHg, p< 0.001) and PAAT increased by
0.012– 0.002 sec (95% CI 0.016 to 0.007, p< 0.001) after the
treatment with bosentan, compared with the baseline value
(Table 3). Moreover, the combination of bosentan and oxygen
increased PAAT more than bosentan alone (0.011 – 0.002 sec,
95% CI 0.006 to - 0.017, p < 0.001), but had the same decreased
effect on the systolic PAP (- 2.0 – 3.1 mmHg, 95% CI - 4.6 to
0.6, p< 0.2) (Table 2). CO, HR, and systemic BP were not sig-
nificantly altered in response to single dose of bosentan
compared with baseline.
Discussion
This study found that 1) the -3a/-4a ET-1 gene polymor-
phism is associated with HAPH in highlanders, 2) plasma
ET-1 levels are significantly higher in high altitude residents
with HAPH compared with high-altitude healthy controls,
and 3) the dual ET receptor antagonist effectively reduced
Table 1. Characteristics of Highlanders
HAPH (n = 88) Healthy (n = 50)
Age, year 49.7 – 14.8 48.8 – 16.2
Gender (m/f) 69/19 47/3
PAP mean, mm Hg 32.4 – 6.8 20.5 – 7.2*
FEV1, % predicted 93.0 – 11.0 92.0 – 13.0
FVC, % predicted 94.0 – 15.0 94.0 – 14.0
Smoking (m/f) 12/0 19/0
Data are presented as mean – SD. PAP mean – mean pulmonary
artery pressure, measured by right heart catheterization; FEV1 –
forced expiratory volume in 1 second; FVC – forced vital capacity;
*p < 0.001 – HAPH vs. Healthy.
Table 2. -3a/-4a Polymorphism





Groups -3a/-3a -3a/-4a -4a/-4a -3a -4a
Healthy
(n = 50)
0.49 (20) 0.42 (30) 0.09 (0) 0.70 (70) 0.30 (30)
HAPH
(n = 88)
0.32 (13) 0.49 (75) 0.19 (0)* 0.57 (101) 0.43 (75)**
*v2 = 11.15; p= 0.0008, **v2 = 4.304; p = 0.03.
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systolic PAP in HAPH, comparable to that seen with oxygen
administration.
Inter-individual susceptibility to HAPH and the response
of pulmonary vessels to hypoxic stimuli strongly suggests a
genetic trait (Westcott et al., 1951). In previous studies, we
found an association between ACE gene polymorphism
and development of HAPH (Morrell et al., 1999; Aldashev
et al., 2002).
ET-1 is a potent endogenous vasoconstrictor and smooth
muscle mitogen (Yanagisawa and Masaki, 1989), and it ap-
pears to play an important role in PAH. For example, plasma
ET-1 levels are increased in animals with experimental PH
(Shirakami et al., 1991; Li et al., 1994; Yang et al., 1997). Ad-
ditionally, it was demonstrated that hypoxia-induced inhibi-
tion of voltage-gated K + channel expression may result from
increased level of ET-1 secondary to induction of Hif1a
(Whitman et al., 2008). ET-1 levels are increased in subjects
who develop HAPE compared with HAPE-resistance subjects
and correlates with level of PAP (Sartori et al., 1999). Also, the
increase in PAP during exposure to high altitude relates to
plasma ET-1 concentration (Goerre et al., 1995). In the ACME-
1 study, Modesti and co-authors showed that ET-1 plays a
significant role in pulmonary vascular vasoconstriction dur-
ing adaptation to high altitude (Modesti et al., 2006).
First, we have measured the plasma level of ET-1 in
highlanders with and without HAPH. We have found that
the level of ET-1 is significantly higher in highlanders with
HAPH compared with healthy. We then studied the role of
3a/4a ET-1 gene polymorphism in Kyrgyz highlanders, be-
cause it has been shown that -3a/-4a ET-1 gene polymor-
phism is functional and associated with circulating ET-1
levels. Furthermore, the -4a allele is associated with higher
plasma ET-1 levels in patients with essential hyperten-
sion (Tanaka et al., 2004) and chronic heart failure (Vasku
et al., 2002). Rajput and co-authors have reported that the
-3a/-3a genotype is associated with lower ET-1 levels than
the -3a/-4a genotype in high altitude natives (Rajput et al.,
2006). However the ET-1 gene polymorphism was not in-
vestigated in high altitude residents with HAPH. In our
study, we found that the frequency of mutant -4a ET-1 allele
was significantly higher in highlanders with HAPH as
compared with healthy highlanders. The absence of the -4a/
-4a homozygous genotype in our study population suggests
a selection pressure against this genotype, which could be
associated with a more severe pulmonary vasoconstriction
response to hypoxia and the early onset of a pulmonary
hypertensive phenotype. But this requires confirmation in a
large cohort study.
We went on to confirm that the plasma ET-1 level is related
to 3a/4a ET-1 gene polymorphism in Kyrgyz highlanders. In
our study, we found that in highlanders with 3a/4a genotype
the ET-1 concentration is relatively, but not significantly
higher than in subjects with homozygous 3a/3a genotype.
Unfortunately, a small number of patients was entered in this
study. However, the changes in plasma ET-1 concentration do
not necessarily reflect changes in local tissue, because (as has
been shown) ET-1 is mainly a paracrine mediator and only
20% of produced ET-1 is released into the blood stream
(Wagner et al., 1992). Nonetheless, additional study on a large
cohort is required.
FIG. 1. Endothelin-1 plasma level in highlanders. (A) ET-1 plasma is significantly higher in highlanders with HAPH,
*p< 0.001, HAPH vs, Healthy. (B) Lack of association between ET-1 plasma level and genotype of - 3a/-4a ET-1 gene
polymorphism. ET-1 plasma level measured in 37 highlanders.
Table 3. Effects of Bosentan and Oxygen on PAP in Highlanders
1st day (n = 15) 2nd day (n= 15)
Parameters Baseline Oxygen Baseline Bosentan Bosentan +Oxygen
PAAT, sec 0.086 – 0.003 0.102– 0.008* 0.086– 0.003 0.098– 0.003* 0.110– 0.005*{
PAPsyst, mm Hg 46.3 – 6.2 38.0 – 7.7* 46.4 – 6.2 37.0 – 7.2* 33.0 – 5.8*
CO, l/min 5.9 – 1.1 6.1 – 1.7 5.9 – 1.0 6.0 – 1.5 5.9 – 1.0
BP systolic, mm Hg 129.0 – 17.1 125.0– 10.1 127.5– 14.6 126– 13.7 123 – 9.7
BP diastolic, mm Hg 82.0 – 7.4 79– 6.2 80.0 – 1.6 78– 5.7 77 – 4.7
HR, bpm 83.0 + 14.6 79.0 – 11.6 80.0 – 13.1 83.0 – 13.5 81 – 10.5
SaO2, % 88.4 – 2.3 97.0 – 2.1* 88– 2.1 89– 1.6 96 – 0.8*
Data are presented as mean– SD. PAAT – pulmonary artery acceleration time, PAPsyst – pulmonary artery systolic pressure, CO - cardiac
output, BP – blood pressure, HR – heart rate, bpm – beats per minute, *p< 0.05 – vs. baseline; {p< 0.05 – vs. bosentan.
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The ideal treatment of HAPH is migration to low altitude
(Leon-Velarde et al., 2005), but due to economic reasons it is
almost impossible or not applicable. Alternative ways such as
oxygen supplementation have been used, but it has some
limitations. It was shown by Groves and co-authors in Op-
eration Everest II study that in healthy volunteers acute oxygen
breathing at simulated altitude 7620 m lowered mean PAP, but
not calculated pulmonary vascular resistance (PVR), due to CO
also decreased (Groves et al., 1987). However, several studies
demonstrated that oxygen decreases PAP in highlanders and
reduces the increase in PAP during exercise (Grover et al., 1966;
Penaloza and Sime, 1971). In our study, we demonstrated that
oxygen markedly reduced systolic PAP, improved PAAT, and
did not change CO. In our study, oxygen supplementation
blunted hypoxic pulmonary vasoconstriction in high altitude
residents, but did not reverse PAP till normal value, due to the
presence of remodeling of the pulmonary vessels, as was
shown previously (Aldashev et al., 2002).
Taken into account that ET-1 plays an important role in
high altitude-related illness, we decided to investigate the
effect of dual ET receptors blocker on PAP in highlanders with
HAPH. Bosentan is known to reduce PAP, and improve ex-
ercise capacity and quality of life in patients with PAH
(Channick et al., 2001; Rubin et al., 2002). Modesti and co-
authors demonstrated that bosentan effectively attenuates
hypoxic pulmonary vasoconstriction in healthy subjects dur-
ing acclimatization to high altitude, but was also associated
with reduction of urinary volume and free water clearance
(Modesti et al., 2006). In another study, a single dose of bo-
sentan significantly blunted the hypoxia-induced increase in
PASP at rest, but not during exercise (Pham et al., 2010). In line
with our study, authors demonstrated that bosentan had no
effect on CO, oxygen saturation, and systemic arterial pres-
sure. Additionally, Faoro and co-authors showed that a single
oral dose of bosentan improves aerobic exercise capacity and
attenuates hypoxic pulmonary vasoconstriction (Faoro et al.,
2009). Also, Olfert and co-authors demonstrated that bo-
sentan improves arterial oxygenation during short-term ex-
posure to acute hypoxia (Olfert et al., 2011). However, Seheult
and colleagues (2009) recently published data where they
initiated treatment with bosentan in healthy nonacclimatized
volunteers 5 days before ascent and continued for 2 days at
altitude (Seheult et al., 2009) and demonstrated that bosentan
does not reduce resting or exercise systolic PAP or improve
exercise capacity. Moreover, in their hands, bosentan was
associated with lower hemoglobin oxygen saturation during
exercise at altitude. The authors suppose that it might be due
to bosentan’s fluid retention effect on the kidney, and that
administration before ascent to altitude may result in more
pulmonary alveolar fluid or interstitial pulmonary edema and
worsen ventilation–perfusion relationships.
All of these studies investigated the effectiveness of bo-
sentan in healthy human subjects during short-term accli-
matization to high altitude or simulated hypoxic challenge,
but the acute effects of ET-1 inhibition in patients with chronic
HAPH until now was not studied. In our study, we demon-
strated that bosentan is as effective as oxygen in acute re-
duction of PAP at high altitude. The combination of bosentan
and oxygen breathing led to further improvement in PAAT,
but not systolic PAP, compared to bosentan alone. We know
at this point that PAAT correlates well with both sPAP and
mPAP in patients with congenital heart disease (Kosturakis
et al., 1984) or HAPH (Kojonazarov et al., 2007); however,
PAAT has not become as widely used as the tricuspid re-
gurgitation method. Moreover, the measurement of the
maximal velocity of the tricuspid regurgitant jet is more reli-
able and accurate than PAAT, especially in assessing the
changes after therapeutic interventions (Chow et al., 1988).
Nonetheless, the noninvasive measurement of PAP is less
precise than cardiac catheterization, which remains the gold
standard. But there are practical problems with using this
technique at altitude.
Summarizing all our findings, we would like to state that
ET-1 contributes to the development of HAPH and 3a/4a ET-
1 gene polymorphism associated with high PAP in high alti-
tude residents. Our direct measurements of PAP pressure
were performed at low altitude, which might be one of the
limiting factors in our study. The descent to low altitude re-
verses hypoxia-induced pulmonary vascular vasoconstric-
tion, but also remodels the pulmonary vessels. It has been
demonstrated that PAP reversed to normal values in high
altitude natives after their staying 2 years at sea level. How-
ever, despite the normal PAP after 2 years at sea level, the
pulmonary pressure response to exercise was similar to that
observed at high altitude (Sime et al., 1971; Penaloza et al.,
2007). Additionally, Grover et al. (I966) reported a case in
which high mean PAP decreased substantially 11 months
after residence at sea level. Moreover, it was demonstrated
that PAP in patients with chronic mountain sickness time-
dependently reduced after descending to sea level, due to
suppression of hypoxic vasoconstriction and progressive re-
duction of polycythemia (Penaloza and Sime, 1971). These
observations may suggest that reversing the pulmonary ar-
terial pressure of high altitude natives to normal levels re-
quires a prolonged stay at sea level because of the slow
involution of the anatomical changes of pulmonary vessels
(Penaloza et al., 2007). Nevertheless, taken into account all of
these issues, probably it would be more suitable to measure
PAP at high altitude as it may increase the number of subjects
with HAPH.
We have also observed for the first time that a single dose of
bosentan effectively decreased PAP in highlanders, substan-
tiating the important role of ET-1 in the development of
HAPH. However, the low number of patients involved in the
acute bosentan study can be considered as a limitation.
Nonetheless, an additional study of the long-term effect of ET
receptor blockade on pulmonary hypertension and renal
function in a larger cohort of highlanders with HAPH is
warranted.
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